Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study to Evaluate the Safety and Tolerability of JL15003 Injection in Patients With Recurrent Glioblastoma

NCT07497373 is registered in ClinicalTrials.gov with Jecho Biopharmaceuticals Co., Ltd. as lead sponsor.

NCT NCT07497373
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07497373 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study to Evaluate the Safety and Tolerability of JL15003 Injection in Patients With Recurrent Glioblastoma
Lead sponsor
Jecho Biopharmaceuticals Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
November 16, 2022
Completion date
May 23, 2024
Enrollment
17 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent glioblastoma multiforme(gbm)